rapid, sustained, consistent clinical response
ACR20 clinical response was observed in MTX-IR and TNF-IR patients as early as 2 weeks in MOBILITY and as quickly as 4 weeks in TARGET, respectively, after the first dose. 1
‡DMARD(s) in TARGET and MOBILITY include MTX, sulfasalazine, leflunomide, and/or hydroxychloroquine.
KEVZARA provided patients with uncontrolled RA
fast, lasting clinical improvement1
§P<0.0001, P value is for descriptive purposes only and is not adjusted for multiplicity.
MTX-IR=methotrexate inadequate response; TNF-IR=tumor necrosis factor inhibitor inadequate response or intolerant; ACR20=American College of Rheumatology 20% improvement criteria; MTX=methotrexate; q2w=once every 2 weeks; DMARDs=disease-modifying antirheumatic drugs.
Week 16: KEVZARA 200 mg + MTX: 57% (229/399) vs placebo + MTX: 42% (169/398);
Week 52: KEVZARA 200 mg + MTX: 48% (190/399) vs placebo + MTX: 26% (104/398)
*Minimal clinically important difference. HAQ-DI change from baseline ≥0.3 units.
HAQ-DI=Health Assessment Questionnaire-Disability Index; MTX-IR=methotrexate inadequate response; TNF-IR=tumor necrosis factor inhibitor inadequate response or intolerant; ITT=intent to treat; MTX=methotrexate; q2w=once every 2 weeks; DMARDs=disease-modifying antirheumatic drugs.
56% OF MTX-IR PATIENTS HAD NO RADIOGRAPHIC PROGRESSION WITH KEVZARA
AT 52 WEEKS vs 39% OF PATIENTS TREATED WITH PLACEBO2*
greater inhibition of joint damage progression
with KEVZARA 200 mg + MTX vs placebo + MTX2
*Defined as mean change from baseline in total Sharp score of ≤0.
†Based on post hoc comparisons of mean change in mTSS per treatment group. Week 52 analysis employs linear extrapolation method to impute missing or post rescue data.2
MTX-IR=methotrexate inadequate response; mTSS=modified total Sharp score; MTX=methotrexate.
INTERPRET WITH CAUTION